key: cord-0753217-76vzswxc authors: Marin O, María Mónica; García P, Ángel Alberto; Muñoz V, Oscar Mauricio; Castellanos R, Julio César; Cáceres M, Edward; Pacheco, David Santacruz title: PORTABLE SINGLE-LEAD ELECTROCARDIOGRAM DEVICE IS ACCURATE FOR QTc EVALUATION IN HOSPITALIZED PATIENTS date: 2021-06-28 journal: Heart Rhythm O2 DOI: 10.1016/j.hroo.2021.06.005 sha: d09d2db65b43256103a9f7384e3a286bcf89881f doc_id: 753217 cord_uid: 76vzswxc BACKGROUND: Many commonly used drugs can prolong the QTc interval (QTc), which can lead to potentially life-threatening arrhythmias. In the current era of COVID-19 pandemic, it is worth mentioning that the disease itself and several drugs used for its treatment have been associated with QTc prolongation. OBJECTIVE: To evaluate the agreement and clinical precision of a portable single-lead ECG device to measure the QTc interval compared to the standard 12-lead ECG. METHODS: In sequential tests, QTc of ECG recordings obtained with the device KardiaMobile (KM-1L) (AliveCor®) were compared to QTc obtained with conventional 12-lead ECG. Agreement was evaluated using Bland-Altman plots and the Lin's concordance coefficient. Consistency between the two devices in determining QTc prolongation (QTc ≥470 ms in males, or ≥480 ms in females), was evaluated with kappa statistics. RESULTS: 128 patients with a presumed or confirmed diagnosis of COVID-19 admitted to a University Hospital were included. QTc intervals measured with KM were similar to QTc measured with conventional ECG (442.45±40.5 vs. 441.65±40.3 ms, p:0.15). Bland–Altman analysis showed no significant difference in QTc values (average difference of -0.797, 95% Limits Of Agreement:-13.179;11.585). Lin's concordance coefficient showed an excellent agreement (0.988, p<0.001). Concordance between the two devices for determining QTc prolongation was excellent (Kappa>0.90). CONCLUSION: ECG recordings obtained with KM-1L allow an accurate QTc interval assessment. Considering its simplicity of use, this approach has advantages over conventional ECG and can provide an alternative for the evaluation of QTc in hospitalized patients, during the current time of pandemic by COVID-19 and beyond. Prolongation of QTc interval may cause potentially fatal cardiac arrhythmias, such as Torsades des Pointes (TdP) (1) . Multiple risk factors have been associated with QTc prolongation, including: congenital QTc prolongation, female gender, age greater than 65 years, ischemic cardiomyopathy, severe bradycardia, electrolyte imbalance and liver/kidney insufficiency. Also, more than 170 drugs may prolong QTc interval, including anti-arrhythmics, anti-psychotics, and anti-fungal agents (2) . In patients with risk factors, QTc interval monitoring with 12-lead derivation ECG is recommended to prevent fatal arrhythmia due to QTc prolongation. Rapid expansion of the COVID-19 pandemic has driven a worldwide use of a variety of drugs for first-line therapy and prophylaxis. Pharmacological treatments have included offlabel use of anti-inflammatory, anti-viral, and anti-parasite drugs, among others, some with the potential risk of QTc interval prolongation. Such drugs are potential inductors of TdP and ventricular fibrillation, increasing the risk of sudden cardiac death. SARS-CoV2 infection also increases cytokine levels, especially IL-6. IL-6 directly blocks the human ether-à-go-go-related gene (hERG) potassium ion channel, with the consequent prolongation of action potential duration and delay in phase 3 of repolarization, causing QTc prolongation and risk of TdP development (3, 4) . Performing 12-lead ECG in patients with suspected or confirmed COVID-19 increases the risk of infection for patients without this disease and for healthcare workers (5, 6) . To reduce the risk of SARS COV-2 infection, easy-to-use alternatives such as portable single-lead ECG devices (e.g. Kardia mobile, iWatch) have been proposed for evaluating QTc. Such devices have proven to be accurate in detecting atrial fibrillation compared to 12-lead ECG (gold standard) and have been used for this purpose in clinical practice (7) (8) (9) (10) . However, information on the diagnostic accuracy of portable single-lead ECG devices is limited, not only for COVID-19 patients but also for the general population. The goal of the present study is to evaluate the numeric and clinical precision of a portable single-lead ECG device to measure QTc interval as compared to the standard 12-lead ECG for its use in hospitalized patients. We include patients with confirmed or suspected SARS COV-2 infection. To perform a recording, one finger of each hand (regardless of which fingers) must rest on the electrodes of the KardiaMobile device for at least 30 seconds. This technique automatically produces an electrocardiographic recording in DI in the Kardia® app. The recording is saved in PDF format, labeled and sent by e-mail for analysis (11, 12) . For each patient a KM tracing and a conventional 12-lead ECG were performed consecutively, and then compared. For each tracing, average QTc was calculated using the Bazett's formula, with three consecutive QTs and the corresponding RR intervals. In conventional ECG, DI, DII, and V5 derivations were used to measure QT intervals. Three experts investigators performed blind measurements and defined QT and QTc values by consensus. Figure 1 presents an example of tracing with a KM device and with a conventional ECG in one patient of the study. General characteristics of the population were analyzed using descriptive statistics. The difference among QTc values was analyzed using a paired t-test to determine the mean difference. The Bland-Altman analysis was used to test the agreement between QTc measured with conventional 12-lead ECG and portable ECG device (13) . Additionally the Lin's Records of 128 patients were evaluated, 47.7 % men and 52.3 % women. The average age was 60.3 years. Cardiopathy was the most frequent cause of hospitalization (31.3 %). History of heart failure, use of potentially QT interval-prolonging drugs, and history of high blood pressure were present in 41.4 %, 50.8 %, and 60.9 % of patients, respectively. SARS-CoV-2 was confirmed in 25.8 % of patients. Table 1 Numeric precision, defined as the proportion of measurements in which QT interval measurement from Kardia Mobile had less than 10 ms of difference with the measurement in conventional ECG, was 71.9 % for uncorrected QT interval and 93 % for QTc. The patient with the greatest variation in heart rate had a difference of 10 beats between the two assessment methods. Numerical precision compared by subgroups only found a difference in the SARS-CoV-2 infection category. Numerical precision was 85% in this group of patients versus 96.6% in cases in which infection was ruled out (p = 0.017). The greatest variation in the heart rates obtained in the different evaluation methods was observed in the group of patients with probable or confirmed COVID-19. No differences were found in categories of gender, history of heart failure, blood hypertension, and use of QT-prolonging medications ( Table 2) . Table 3) . Our study evaluated the agreement between a portable ECG device and the conventional ECG for QTc interval evaluation and the numerical and clinical precision of the device. The study found an excellent agreement and no statistically significant differences in the QTc interval measurement using these different methods. Previous studies evaluating portable ECG-device precision for QTc were limited by the small number of evaluated patients or by the inclusion of healthy subjects and hospitalized ill patients (15, 16) . Even so, the results were similar to those in this study. A recent study in the COVID-19 pandemic evaluated 100 consecutive patients recruited in the ambulatory setting or in the emergency room. An ECG tracing obtained with a smart watch yielded corrected QT interval measurements that were adequate for reading in 85% of patients when the device was worn on the left wrist. That value rose to 94% when the position of the smart watch was modified to improve the quality of electrocardiographic tracing and amplitude of T wave. Once the optimal position was found, concordance between devices was excellent, similar to the results in our study (17) . , to evaluate if they were able to record their own ECG tracings at least once without any assistance. They found that the device had the ability to provide reliable QT/QTc interval measurements. Hospitalized patients were able to perform recordings when requested after receiving simple instructions at the time of first use. Unlike this 6-lead device, we used a single-lead device and found excellent agreement compared to the conventional 12-lead ECG when evaluating QTc using the Bazett formula, suggesting that a simpler device could be equally reliable. Future studies are needed to assess whether patients themselves, as reported by Frisch, could perform the measurement with a single-lead device (18) . A portable ECG device with 6 leads has been evaluated in settings different to COVID-19. An artificial intelligence (AI)-enabled 12-lead ECG algorithm to determine the QTc, was evaluated in 686 patients with genetic heart disease (50% with long QT syndrome). A strong agreement was observed between a deep neural network-predicted QTc values derived from manual ECG (mECG) tracings and those annotated from 12-lead ECGs by a QT expert (-0.45±24.73 ms), with values very similar to our findings (19) . These results suggest that QTc measured with wearable devices could be applied for ambulatory surveillance, which is likely to increase over time, even after the pandemic has subsided. Numeric precision of KM was similar for categories of sex, history of heart failure, blood hypertension, and use of QT prolonging drugs. An interesting finding is that concordance was lower in patients with confirmed SARS-CoV-2 infection compared to patients without the infection. This is the first time this situation has been described. One possible explanation is that the greatest variation in the heart rates obtained by the different evaluation methods was observed in this group of patients. Autonomic abnormalities on autonomic tests have been described in these patients, and could be related with the changes in the heart rates observed in our study (20) . This may be due to abnormalities related to the viral infection or the clinical status of patients. It is necessary to evaluate these hypotheses in the future in other studies. Differences were also identified between the QT and QTc intervals, which can also be explained by the variations between the heart rate values described. It is important to mention that it was necessary to modify the position in which the electrocardiographic record was taken with the KM device from supine to sitting in some patients in our study, to improve the quality of the tracing obtained. Variation of heart rate (HR) has been associated with postural changes. Resting HR is faster in up-right postures such as standing and sitting, compared with the lying position. In a recent study, it was described that postural change supine to sitting increases heart rate by 10 beats per minute in both genders, and postural change supine to standing increases heart rate by 30 beats per minute in females and males. The mechanisms proposed for such differences have been related to baroreceptor stimulation as well as the regulation of cardiovascular hormones (21-31). Postural changes from supine to sitting or standing are also known to affect QT / QTc intervals or QT dispersion. Stretching of the QT interval may partly explain these findings. This is the phenomenon that occurs when the QT interval is not shortened in proportion to the shortening of the RR interval (when HR increases). Taking into account that the measurement of the QT interval J o u r n a l P r e -p r o o f is directly related to the RR interval, several mathematical formulas have been designed to ''correct'' the QT interval and adapt it to the heart rate or, what is the same, to the RR interval. Therefore, the clinically useful QT interval is the corrected QT interval (32-34). When analyzing the graph obtained by applying the Bland Altman analysis, three outliers were identified close to the limits of agreement, suggesting significant differences between the QTc measured by the device and the conventional 12-lead ECG. The patients with these findings are part of the group of patients with SARS-COV2 infection and they are the ones with the greatest differences in the heart rate values obtained by the different evaluation methods. This study is, to our knowledge, the largest reported to date to assess the accuracy and concordance of the KM device compared to the conventional 12-lead ECG. Our study is also among the first to evaluate the validity of the single-lead KM device specifically for the measurement of the QTc interval. Regarding the limitations of our study, we must emphasize that it was carried out in a single center and with a single device. Furthermore, the number of patients with QTc interval prolongation was relatively small. Further studies are required to evaluate the characteristics of KM in other clinical settings and to strengthen the conclusions in patients with prolonged QTc. Noisy recordings have been reported with the use of the KM device, which can also be a limitation. In our protocol, it was considered necessary to repeat the recordings when noise was identified to obtain clear and interpretable traces. For an Anterior Precordial Lead, the device can be placed on the lower left side of the chest, just below the pectoral muscle (35). This way of obtaining the record was not included in our protocol, but it can be a strategy to solve the difficulty of dealing with noisy traces. The results of this study demonstrate that the single-lead KM has adequate precision and agreement in compare with 12-lead ECG, justifying its clinical use to assess the QTc interval. Because it is quick and convenient to use, KM is ideal for reducing the exposure time of healthcare workers in the COVID-19 pandemic. Further studies should evaluate whether these characteristics are observed in outpatients or in low complexity institutions. Hospital Universitario San Ignacio provided financial resources for this research. The authors have no conflicts to disclose. The director of Hospital Universitario San Ignacio provided the device used for this project. All authors attest they meet the current ICMJE criteria for authorship. The Ethics and Research Committee approved the exemption of informed consent (Approval code: 10/2020). The Ethics and Research Committee of the Faculty of Medicine of Pontificia Universidad Javeriana and Hospital Universitario San Ignacio approved the study. This study was done in accordance with the standards specified in the International Council for Harmonization Guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki. Data are shown by number (percentage of total patients in the group) Kappa value ± standard error is also shown J o u r n a l P r e -p r o o f What clinicians should know about the QT interval Risk factors for QTcprolongation: Systematic review of the evidence Ventricular fibrillation storm in coronavirus 2019 IL-6 (interleukin 6) blockade and heart rate corrected QT interval prolongation in COVID-19 Recomendaciones para la medición del intervalo QT durante el uso de medicamentos para el tratamiento de infección por COVID-19. Sociedad Latinoamericana del Ritmo Cardiaco (LAHRS) Ventricular arrhythmia risk due to hydroxychloroquine-azithromycin treatment for COVID-19 Wireless smartphone ECG enables largescale screening in diverse populations iPhone ECG application for community screening to detect silent atrial fibrillation: a novel technology to prevent stroke Validation of a smartphone-based event recorder for arrhythmia detection Clinical validation of a low-power and wearable ECG patch for long term full-disclosure monitoring How-to-set-up Ubiquitous wireless ECG recording: a powerful tool physicians should embrace Statistical methods for assessing agreement between two methods of clinical measurement A concordance correlation coefficient to evaluate reproducibility Comparison of QT Interval Readings in Normal Sinus Rhythm Between a Smartphone Heart Monitor and a 12-Lead ECG for Healthy Volunteers and Inpatients Receiving Sotalol or Dofetilide QTC intervals can be assessed with the AliveCor heart monitor in patients on dofetilide for atrial fibrillation Validating QT-Interval Measurement Using the Apple Watch ECG to Enable Remote Monitoring During the COVID-19 Pandemic Initial Experience in Monitoring QT Intervals Using a Six-lead Contactless Mobile Electrocardiogram in an Inpatient Setting Artificial Intelligence-Enabled Assessment of the Heart Rate Corrected QT Interval Using a Mobile Electrocardiogram Device Autonomic dysfunction following COVID-19 infection: an early experience Sex differences in heart rate responses to postural provocations Mechanisms of initial heart rate response to postural change Autonomic mechanisms in the initial heart rate response to standing Even slight movements disturb analysis of cardiovascular dynamics The authors are especially grateful to the nursing staff of the Cardiology Unit of Hospital Universitario San Ignacio. J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 1. ECG recordings obtained with portable single-lead devices are feasible and allow accurate assessment of the QTC interval. In this study, we obtained a very good correlation of the QTc interval measured with the KardiaMobile 1-L device compared to the standard ECG. 2. The advantage of the KardiaMobile 1-L device is the simplicity of its use, so it can be used by both healthcare personnel and patients themselves, and could be applied for ambulatory monitoring, which is likely to increase over time even after the pandemic has subsided. 3. An interesting finding is that concordance was lower in patients with SARS-COV-2 infection compared to patients without the infection. This group of patients also presented the greatest variation in the heart rates obtained by the different evaluation methods, which may be related to autonomic anomalies that have been described in these patients in autonomic tests.